Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT - Jayne, David; Walsh, Michael; Merkel, Peter A; Peh, Chen Au; Szpirt, Wladimir; Puéchal, Xavier; Fujimoto, Shouichi; Hawley, Carmel; Khalidi, Nader; Jones, Rachel; Flossmann, Oliver; Wald, Ron; et al. (Health Technology Assessment, 2022)
Keywords: anca; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy; Autoantibodies; Autoantibodies - therapeutic use; Cost-Benefit Analysis; Cyclophosphamide; Cyclophosphamide - therapeutic use; Cytoplasm; glomerulonephritis; glucocorticoids; Glucocorticoids - therapeutic use; Humans; Kidney Failure, Chronic; Kidney Failure, Chronic - therapy; lung haemorrhage; Medical technology; Myeloblastin; Peroxidase; Peroxidase - therapeutic use; plasma exchange; Prednisolone; Prednisolone - therapeutic use; R855-855.5; randomised; Rituximab; Rituximab - therapeutic use; vasculitis; GLOMERULONEPHRITIS; PLASMA EXCHANGE; GLUCOCORTICOIDS; RANDOMISED; ANCA; VASCULITIS; LUNG HAEMORRHAGE